High-dose interleukin-2 therapy related adverse events and implications on imaging.

Journal Article (Journal Article)

High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate immune system. HDIL-2 therapy is associated with a wide spectrum of immune-related adverse events (irAEs) that can be radiologically identified. HDIL-2 toxicity can manifest in multiple organ systems, most significantly leading to cardiovascular, abdominal, endocrine, and neurological adverse events. The collective impact of the irAEs and the rise of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors led to the demise of HDIL-2 as a primary therapy for mRCC and metastatic melanoma. However, with innovation in ICIs and the creation of mutant IL-2 conjugates, there has been a drive for combination therapy. Knowledge of the HDIL-2 therapy and HDIL-2 related adverse events with radiology relevance is critical in diagnostic image interpretation.

Full Text

Duke Authors

Cited Authors

  • Shah, NR; Declouette, B; Ansari-Gilani, K; Alhomoud, MS; Hoimes, C; Ramaiya, NH; Güler, E

Published Date

  • September 2021

Published In

Volume / Issue

  • 27 / 5

Start / End Page

  • 684 - 689

PubMed ID

  • 34559052

Pubmed Central ID

  • PMC8480956

Electronic International Standard Serial Number (EISSN)

  • 1305-3612

Digital Object Identifier (DOI)

  • 10.5152/dir.2021.20503


  • eng

Conference Location

  • Turkey